Summit Therapeutics Sees Unusually Large Options Volume (NASDAQ:SMMT)

Summit Therapeutics PLC (NASDAQ:SMMT) was the target of some unusual options trading on Friday. Traders acquired 20,849 call options on the stock. This is an increase of 147% compared to the average daily volume of 8,434 call options.

Insider Activity at Summit Therapeutics

In other news, CEO Robert W. Duggan purchased 3,810,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were purchased at an average price of $13.12 per share, for a total transaction of $49,987,200.00. Following the purchase, the chief executive officer directly owned 573,883,879 shares of the company’s stock, valued at $7,529,356,492.48. This represents a 0.67% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mahkam Zanganeh purchased 3,810,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were purchased at an average cost of $13.12 per share, for a total transaction of $49,987,200.00. Following the transaction, the chief executive officer owned 573,883,879 shares of the company’s stock, valued at $7,529,356,492.48. This trade represents a 0.67% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 7,870,000 shares of company stock valued at $103,616,900 in the last three months. 83.50% of the stock is currently owned by company insiders.

Institutional Trading of Summit Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in SMMT. Price T Rowe Associates Inc. MD raised its holdings in Summit Therapeutics by 106.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,371,415 shares of the company’s stock worth $163,907,000 after purchasing an additional 4,832,592 shares in the last quarter. Baker BROS. Advisors LP boosted its holdings in Summit Therapeutics by 7.9% in the 4th quarter. Baker BROS. Advisors LP now owns 36,391,063 shares of the company’s stock valued at $636,480,000 after purchasing an additional 2,668,089 shares in the last quarter. Norges Bank acquired a new position in Summit Therapeutics during the 4th quarter worth approximately $24,030,000. TD Asset Management Inc increased its position in Summit Therapeutics by 124.2% during the 4th quarter. TD Asset Management Inc now owns 1,205,272 shares of the company’s stock worth $21,080,000 after purchasing an additional 667,742 shares during the period. Finally, Polymer Capital Management HK LTD raised its stake in shares of Summit Therapeutics by 73.9% during the 4th quarter. Polymer Capital Management HK LTD now owns 1,421,155 shares of the company’s stock worth $24,856,000 after buying an additional 603,879 shares in the last quarter. Hedge funds and other institutional investors own 4.61% of the company’s stock.

Trending Headlines about Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Summit reported updated Phase III survival data for its HARMONi lung cancer study and said its lead drug ivonescimab continues to advance, including new development collaborations that broaden its pipeline optionality. Article Title
• Positive Sentiment: Unusually heavy options activity, with call volume far above normal, suggests traders are positioning for a possible rebound or additional catalyst-driven upside.
• Neutral Sentiment: The company’s Q2 earnings call and presentation focused on clinical and operational progress, keeping attention on future data readouts rather than near-term revenue generation. Article Title
• Neutral Sentiment: HC Wainwright reaffirmed a neutral rating, reinforcing that analysts remain cautious while waiting for clearer evidence that ivonescimab can deliver commercially meaningful results. Article Title
• Negative Sentiment: Summit posted a wider-than-expected Q2 loss with no revenue, highlighting continued cash burn and reliance on future clinical success to justify its valuation. Article Title
• Negative Sentiment: An article noted that analyst expectations were being tempered after the initial lung cancer survival data, which may be pressuring sentiment and contributing to the stock’s recent weakness. Article Title

Analysts Set New Price Targets

SMMT has been the topic of a number of recent research reports. Sanford C. Bernstein began coverage on shares of Summit Therapeutics in a report on Thursday, May 21st. They issued an “underperform” rating and a $7.70 target price on the stock. Piper Sandler lowered their price objective on shares of Summit Therapeutics from $17.00 to $16.00 and set a “neutral” rating on the stock in a research report on Friday, May 1st. Citigroup began coverage on shares of Summit Therapeutics in a research report on Wednesday, April 8th. They set a “buy” rating on the stock. Guggenheim dropped their price objective on shares of Summit Therapeutics from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday. Finally, Wall Street Zen cut shares of Summit Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $26.15.

Summit Therapeutics Trading Down 8.8%

NASDAQ:SMMT opened at $13.66 on Friday. Summit Therapeutics has a 12-month low of $12.55 and a 12-month high of $30.98. The stock’s 50 day simple moving average is $15.03 and its 200-day simple moving average is $16.68. The firm has a market cap of $10.60 billion, a P/E ratio of -12.20 and a beta of -1.26.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings results on Thursday, July 23rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). Research analysts forecast that Summit Therapeutics will post -1.18 EPS for the current fiscal year.

About Summit Therapeutics

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.